Literature DB >> 7981591

Expression of dystrophin-associated glycoproteins during human fetal muscle development: a preliminary immunocytochemical study.

F M Tomé1, K Matsumura, M Chevallay, K P Campbell, M Fardeau.   

Abstract

An immunocytochemical study was performed on quadriceps muscle from eight fetuses ranging from 12 weeks of gestation to term, using antibodies against the dystrophin-associated proteins, in order to evaluate the developmental expression of these proteins. For comparison, antibodies against dystrophin and utrophin were also used. The expression of the 59 kDa dystrophin-associated protein was simultaneous with that of dystrophin, which is also a subsarcolemmal protein. The extracellular glycoprotein of 156 kDa (alpha-dystroglycan) and the transmembrane glycoprotein of 43 kDa (beta-dystroglycan) appeared to be expressed later. The transmembrane glycoproteins of 50 kDa (adhalin) and 35 kDa were fully expressed at an even later stage of fetal muscle development. This study suggests that the subsarcolemmal proteins may have an essential role in the assembly of the transmembrane and extracellular components of the dystrophin-glycoprotein complex during fetal muscle development. The knowledge obtained from observing the developmental expression of these proteins may contribute to the understanding of the molecular mechanism of their different involvement in muscle disorders.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981591     DOI: 10.1016/0960-8966(94)90070-1

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  12 in total

Review 1.  Finding the sweet spot: assembly and glycosylation of the dystrophin-associated glycoprotein complex.

Authors:  Dewayne Townsend
Journal:  Anat Rec (Hoboken)       Date:  2014-09       Impact factor: 2.064

2.  2015 William Allan Award.

Authors:  Kay E Davies
Journal:  Am J Hum Genet       Date:  2016-03-03       Impact factor: 11.025

3.  The complex-type oligosaccharide binding lectin Datura stramonium agglutinin detects type II A muscle fibres in the branchial biceps from man and cat.

Authors:  S Kirkeby; T Animashaun; R C Hughes
Journal:  J Muscle Res Cell Motil       Date:  1997-02       Impact factor: 2.698

4.  Soluble Heparin Binding Epidermal Growth Factor-Like Growth Factor Is a Regulator of GALGT2 Expression and GALGT2-Dependent Muscle and Neuromuscular Phenotypes.

Authors:  Megan L Cramer; Rui Xu; Paul T Martin
Journal:  Mol Cell Biol       Date:  2019-06-27       Impact factor: 4.272

5.  Expression of laminin subunits in human fetal skeletal muscle.

Authors:  C A Sewry; M Chevallay; F M Tomé
Journal:  Histochem J       Date:  1995-07

Review 6.  Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.

Authors:  Kristin Wilson; Crystal Faelan; Janet C Patterson-Kane; Daniel G Rudmann; Steven A Moore; Diane Frank; Jay Charleston; Jon Tinsley; G David Young; Anthony J Milici
Journal:  Toxicol Pathol       Date:  2017-10-03       Impact factor: 1.902

7.  Spatio-Temporal Differences in Dystrophin Dynamics at mRNA and Protein Levels Revealed by a Novel FlipTrap Line.

Authors:  Frederique Ruf-Zamojski; Vikas Trivedi; Scott E Fraser; Le A Trinh
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

8.  Second-generation compound for the modulation of utrophin in the therapy of DMD.

Authors:  Simon Guiraud; Sarah E Squire; Benjamin Edwards; Huijia Chen; David T Burns; Nandini Shah; Arran Babbs; Stephen G Davies; Graham M Wynne; Angela J Russell; David Elsey; Francis X Wilson; Jon M Tinsley; Kay E Davies
Journal:  Hum Mol Genet       Date:  2015-05-01       Impact factor: 6.150

9.  Identification of serum protein biomarkers for utrophin based DMD therapy.

Authors:  Simon Guiraud; Benjamin Edwards; Sarah E Squire; Arran Babbs; Nandini Shah; Adam Berg; Huijia Chen; Kay E Davies
Journal:  Sci Rep       Date:  2017-03-02       Impact factor: 4.379

10.  The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.

Authors:  Simon Guiraud; Benjamin Edwards; Arran Babbs; Sarah E Squire; Adam Berg; Lee Moir; Matthew J Wood; Kay E Davies
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.